TearLab Corporation manufactures the TearLab Osmolarity System, a ophthalmic medical device utilized in the eye care industry by ophthalmologists and optometrists for the diagnosis of dry eye and ocular surface disease. TearLab is a well-established company, has been in existence for more than 10 years and has just shipped it's 20 Millionth Test Card.
The TearLab osmolarity test empowers eye care physicians by providing immediate and objective data of a patient’s tear osmolarity. Abnormal osmolarity indicates the presence of dry eye disease, which in turn may impact post-surgical outcomes and contact lens comfort. In addition, osmolarity is now regarded as an essential test by industry societies, and is readily adopted into protocols by eye care physicians.
TearLab is a growing company. Our mission is to pioneer the future of tear film diagnostics to elevate patient care, and our vision is to expand the TearLab product portfolio to match customer needs and market dynamics. TearLab has recently been acquired by Accelmed Partners (a private equity investor), which has positioned TearLab very well to respond to the growing demand within the dry eye disease market.